CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 32 enrolled
Drug / intervention
AZR-MD-001 ointment/semi-solid drugdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04314362
NCT04314362Phase 3Completed
CompareCT.gov

A Single-center, Vehicle-controlled, Study to Evaluate Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)

Azura Ophthalmics·interventional·Posted Mar 19, 2020·Updated Jan 25, 2023

In Brief

A Phase 3 clinical trial evaluating AZR-MD-001 ointment/semi-solid drug for Meibomian Gland Dysfunction. Completed, enrolled 32 participants across 1 site.

Detailed Summary

Single-center, single-masked (the individual(s) performing efficacy and safety measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeibomian Gland Dysfunction
CountriesAustralia
CollaboratorsThe University of New South Wales

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedMar 19, 2020
Enrollment StartJul 14, 2020
Primary CompletionJan 6, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.3 years ago

Interventions

AZR-MD-001 ointment/semi-solid drugdrug

AZR-MD-001 (1.0%) and suitable excipient